FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2036595571> ?p ?o ?g. }

• W2036595571 endingPage "802" @default.
• W2036595571 startingPage "793" @default.
• W2036595571 abstract "Enfuvirtide (Fuzeon™) is an HIV fusion inhibitor, the first drug in a new class of antiretrovirals. The HIV protease inhibitors ritonavir and saquinavir both inhibit cytochrome P450 (CYP450) isoenzymes, and low‐dose ritonavir is often used to boost pharmacokinetic exposure to full‐dose protease inhibitors. These two studies were designed to assess whether ritonavir and ritonavir‐boosted saquinavir influence the steady‐state pharmacokinetics of enfuvirtide. Both studies were single‐center, open‐label, one‐sequence crossover clinical pharmacology studies in 12 HIV‐1‐infected patients each. Patients received enfuvirtide (90 mg twice daily [bid], subcutaneous injection) for 7 days and either ritonavir (200 mg bid, ritonavir study, orally) or saquinavir/ritonavir (1000/100 mg bid, saquinavir/ritonavir study, orally) for 4 days on days 4 to 7. Serial blood samples were collected up to 24 hours after the morning dose of enfuvirtide on days 3 and 7. Plasma concentrations for enfuvirtide, enfuvirtide metabolite, saquinavir, and ritonavir were measured using validated liquid chromatography tandem mass spectrometry methods. Efficacy and safety were also monitored. Bioequivalence criteria require the 90% confidence interval (CI) for the least squares means (LSM) of C max and AUC 12h to be between 80% and 125%. In the present studies, analysis of variance showed that when coadministered with ritonavir, the ratio of LSM for enfuvirtide was 124% for C max (90% confidence interval [CI]: 109%‐141%), 122% for AUC 12h (90% CI: 108%‐137%), and 114% for C trough (90% CI: 102%‐128%). Although the bioequivalence criteria were not met, the increase in enfuvirtide exposure was small (< 25%) and not clinically relevant. When administered with ritonavir‐boosted saquinavir, the ratio of LSM for enfuvirtide was 107% for C max (90% CI: 94.3%‐121%) and 114% for AUC 12h (90% CI: 105%‐124%), which therefore met bioequivalence criteria, and 126% for C trough (90% CI: 117%‐135%). The pharmacokinetics of enfuvirtide are affected to a small extent when coadministered with ritonavir at a dose of 200 mg bid but not when coadministered with a saquinavir‐ritonavir combination (1000/100 mg bid). However, previous clinical studies have shown that such increases in enfuvirtide exposure are not clinically relevant. Thus, no dosage adjustments are warranted when enfuvirtide is coadministered with low‐dose ritonavir or saquinavir boosted with a low dose of ritonavir." @default.
• W2036595571 created "2016-06-24" @default.
• W2036595571 creator A5006710346 @default.
• W2036595571 creator A5009834122 @default.
• W2036595571 creator A5028467654 @default.
• W2036595571 creator A5042614358 @default.
• W2036595571 creator A5059383848 @default.
• W2036595571 creator A5063972076 @default.
• W2036595571 creator A5073300619 @default.
• W2036595571 creator A5084905695 @default.
• W2036595571 creator A5085479766 @default.
• W2036595571 date "2004-07-01" @default.
• W2036595571 modified "2023-10-17" @default.
• W2036595571 title "Lack of Interaction between Enfuvirtide and Ritonavir or Ritonavir-Boosted Saquinavir in HIV-1-Infected Patients" @default.
• W2036595571 cites W1485176492 @default.
• W2036595571 cites W1526872663 @default.
• W2036595571 cites W1848709375 @default.
• W2036595571 cites W1871950822 @default.
• W2036595571 cites W1964470226 @default.
• W2036595571 cites W1970674820 @default.
• W2036595571 cites W1978599196 @default.
• W2036595571 cites W1979267158 @default.
• W2036595571 cites W1979855148 @default.
• W2036595571 cites W1998690882 @default.
• W2036595571 cites W2001038994 @default.
• W2036595571 cites W2005328285 @default.
• W2036595571 cites W2008927246 @default.
• W2036595571 cites W2018204913 @default.
• W2036595571 cites W2031938409 @default.
• W2036595571 cites W2040506631 @default.
• W2036595571 cites W2042153403 @default.
• W2036595571 cites W2058928933 @default.
• W2036595571 cites W2063914923 @default.
• W2036595571 cites W2064900651 @default.
• W2036595571 cites W2075042463 @default.
• W2036595571 cites W2088571092 @default.
• W2036595571 cites W2108524243 @default.
• W2036595571 cites W2133649749 @default.
• W2036595571 cites W2133955454 @default.
• W2036595571 cites W2139502307 @default.
• W2036595571 cites W2153443262 @default.
• W2036595571 cites W2154989704 @default.
• W2036595571 cites W2318563759 @default.
• W2036595571 doi "https://doi.org/10.1177/0091270004266489" @default.
• W2036595571 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15199084" @default.
• W2036595571 hasPublicationYear "2004" @default.
• W2036595571 type Work @default.
• W2036595571 sameAs 2036595571 @default.
• W2036595571 citedByCount "23" @default.
• W2036595571 countsByYear W20365955712017 @default.
• W2036595571 crossrefType "journal-article" @default.
• W2036595571 hasAuthorship W2036595571A5006710346 @default.
• W2036595571 hasAuthorship W2036595571A5009834122 @default.
• W2036595571 hasAuthorship W2036595571A5028467654 @default.
• W2036595571 hasAuthorship W2036595571A5042614358 @default.
• W2036595571 hasAuthorship W2036595571A5059383848 @default.
• W2036595571 hasAuthorship W2036595571A5063972076 @default.
• W2036595571 hasAuthorship W2036595571A5073300619 @default.
• W2036595571 hasAuthorship W2036595571A5084905695 @default.
• W2036595571 hasAuthorship W2036595571A5085479766 @default.
• W2036595571 hasConcept C112705442 @default.
• W2036595571 hasConcept C142462285 @default.
• W2036595571 hasConcept C142724271 @default.
• W2036595571 hasConcept C147483822 @default.
• W2036595571 hasConcept C159047783 @default.
• W2036595571 hasConcept C195616568 @default.
• W2036595571 hasConcept C203014093 @default.
• W2036595571 hasConcept C204787440 @default.
• W2036595571 hasConcept C27081682 @default.
• W2036595571 hasConcept C2776258796 @default.
• W2036595571 hasConcept C2776937687 @default.
• W2036595571 hasConcept C2778037500 @default.
• W2036595571 hasConcept C2779298103 @default.
• W2036595571 hasConcept C2781143361 @default.
• W2036595571 hasConcept C2993143319 @default.
• W2036595571 hasConcept C3013748606 @default.
• W2036595571 hasConcept C42404028 @default.
• W2036595571 hasConcept C71924100 @default.
• W2036595571 hasConcept C87813604 @default.
• W2036595571 hasConcept C98274493 @default.
• W2036595571 hasConceptScore W2036595571C112705442 @default.
• W2036595571 hasConceptScore W2036595571C142462285 @default.
• W2036595571 hasConceptScore W2036595571C142724271 @default.
• W2036595571 hasConceptScore W2036595571C147483822 @default.
• W2036595571 hasConceptScore W2036595571C159047783 @default.
• W2036595571 hasConceptScore W2036595571C195616568 @default.
• W2036595571 hasConceptScore W2036595571C203014093 @default.
• W2036595571 hasConceptScore W2036595571C204787440 @default.
• W2036595571 hasConceptScore W2036595571C27081682 @default.
• W2036595571 hasConceptScore W2036595571C2776258796 @default.
• W2036595571 hasConceptScore W2036595571C2776937687 @default.
• W2036595571 hasConceptScore W2036595571C2778037500 @default.
• W2036595571 hasConceptScore W2036595571C2779298103 @default.
• W2036595571 hasConceptScore W2036595571C2781143361 @default.
• W2036595571 hasConceptScore W2036595571C2993143319 @default.
• W2036595571 hasConceptScore W2036595571C3013748606 @default.
• W2036595571 hasConceptScore W2036595571C42404028 @default.
• W2036595571 hasConceptScore W2036595571C71924100 @default.

• next